The limited available experience suggests that imatinib could be considered as an individualized treatment approach in severe SSc and underscores the need to identify markers for selecting particular patients, who will safely respond to therapeutic inhibition of tyrosine kinases.
Imatinib can decrease tumor size preoperatively and help to improve postsurgical aesthetic appearance and minimize functional impairment.
More micro-GIST are discovered with the development of investigations, rising the question of wait and see policy for some of them.
In locally advanced inoperable patients and metastatic patients, Imatinib is the standard treatment.
Gastrointestinal stromal tumour (GIST).
Imatinib mesylate (Gleevec, Novartis Pharmaceuticals East Manruer, NJ) received accelerated approval on May 10, 2001 for the treatment of patients with chronic myeloid leukemia (CML) in (a) chronic phase after failure of IFN-alpha therapy, (b) accelerated phase, and (c) blast crisis.
Imatinib (Gleevec)Chronic myelogenous leukemia (CML)May 2001Y42,000205.
1, 208.
1, 758.
89Gastrointestinal stromal tumor (GIST)February 2002Y15,000238.
1, 238.
9.
Imatinib was effective against GIST that were positive for KIT protein.
.
